{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T18:16:37Z","timestamp":1773425797365,"version":"3.50.1"},"reference-count":36,"publisher":"FapUNIFESP (SciELO)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sao Paulo Med. J."],"published-print":{"date-parts":[[2008,9]]},"abstract":"<jats:p>CONTEXT AND OBJECTIVE: Osteoporosis is defined as a disease characterized by low bone mass and deterioration of the bone tissue microarchitecture. Teriparatide stimulates the formation and action of osteoblasts, which are responsible for bone formation, thus promoting bone tissue increase. The aim was to assess the effectiveness and safety of teriparatide for treating postmenopausal osteoporosis. METHODS: A systematic review was conducted using the Cochrane Collaboration methodology. RESULTS: 1) Teriparatide 20 \u00b5g or 40 \u00b5g versus placebo: there was a benefit from teriparatide, considering the following outcomes: reduction in the number of new vertebral and non-vertebral fractures, and increased whole-body, lumbar and femoral bone mineral density. 2) Teriparatide 40 \u00b5g versus alendronate 10 mg\/day for 14 months: there was no statistical difference regarding the incidence of new vertebral or non-vertebral fractures, although in the group that received teriparatide there was greater bone mineral density increase in the whole body, lumbar column and femur. 3) Estrogen plus teriparatide 25 \u00b5g versus estrogen: there was a benefit, considering the following outcomes: reduction in the number of new vertebral fractures, and increased whole-body, lumbar and femoral bone mineral density after three years. CONCLUSIONS: When teriparatide is intermittently administered in low doses, it reduces the incidence of vertebral fractures (67%) and non-vertebral fractures (38%) and increases bone mineral density in the lumbar column and femur. There is a need for studies with longer observation in order to allow conclusions regarding the safety and duration of the therapeutic effects.<\/jats:p>","DOI":"10.1590\/s1516-31802008000500007","type":"journal-article","created":{"date-parts":[[2008,12,18]],"date-time":"2008-12-18T15:57:30Z","timestamp":1229615850000},"page":"279-284","source":"Crossref","is-referenced-by-count":18,"title":["Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review"],"prefix":"10.1590","volume":"126","author":[{"given":"Virg\u00ednia Fernandes Mo\u00e7a","family":"Trevisani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Riera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline Mizusaki","family":"Imoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Humberto","family":"Saconato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro Nagib","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"issue":"6603","key":"ref1","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/bmj.295.6603.914","article-title":"Consensus development conference: prophylaxis and treatment of osteoporosis","volume":"295","year":"1987","journal-title":"Br Med J (Clin Res Ed)."},{"issue":"8","key":"ref2","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis JA","year":"1994","journal-title":"J Bone Miner Res."},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s001980170152","article-title":"Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women","volume":"12","author":"Doherty DA","year":"2001","journal-title":"Osteoporos Int."},{"issue":"9321","key":"ref4","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(02)08761-5","article-title":"Diagnosis of osteoporosis and assessment of fracture risk","volume":"359","author":"Kanis JA.","year":"2002","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref5","series-title":"Evidence-based Rheumatology","first-page":"225","volume-title":"Ottawa Methods Group: Osteoporosis","author":"Cranney A","year":"2003"},{"issue":"9","key":"ref6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/ajhp\/60.9.883","article-title":"Current approaches to the prevention and treatment of postmenopausal osteoporosis","volume":"60","author":"Follin SL","year":"2003","journal-title":"Am J Health Syst Pharm."},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","article-title":"Risk of new vertebral fracture in the year following a fracture","volume":"285","author":"Lindsay R","year":"2001","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"issue":"12","key":"ref8","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1007\/s001980170015","article-title":"Impact of hip and vertebral fractures on quality-adjusted life years","volume":"12","author":"Tosteston AN","year":"2001","journal-title":"Osteoporos Int."},{"issue":"9","key":"ref9","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1532-5415.1995.tb05557.x","article-title":"Late physical and functional effects of osteoporotic fracture in women: the Rancho Bernardo Study","volume":"43","author":"Greendale GA","year":"1995","journal-title":"J Am Geriatr Soc."},{"issue":"9","key":"ref10","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/jbmr.5650070902","article-title":"Perspective: How many women have osteoporosis?","volume":"7","author":"Melton LJ 3rd","year":"1992","journal-title":"J Bone Miner Res."},{"issue":"9322","key":"ref11","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)08827-X","article-title":"Treatment of postmenopausal osteoporosis","volume":"359","author":"Delmas PD.","year":"2002","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"issue":"10","key":"ref12","first-page":"1","article-title":"Scientific Advisory Council of the Osteoporosis Society of Canada: 2002 clinical practice guidelines for diagnosis and management of osteoporosis in Canada","volume":"167","author":"Brown JP","year":"2002","journal-title":"CMAJ","ISSN":"https:\/\/id.crossref.org\/issn\/0820-3946","issn-type":"print"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"544","DOI":"10.4158\/EP.9.6.544","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003","volume":"9","year":"2003","journal-title":"Endocr Pract."},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00002512-199915020-00005","article-title":"The bone-building action of the parathyroid hormone: implications for the treatment of osteoporosis","volume":"15","author":"Whitfield JF","year":"1999","journal-title":"Drugs Aging."},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad AR","year":"1996","journal-title":"Control Clin Trials."},{"key":"ref16","series-title":"Cochrane handbook for systematic reviews of interventions 4.2.6","author":"Higgins J","year":"2006"},{"issue":"7","key":"ref17","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1210\/jc.2003-032066","article-title":"Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34)","volume":"89","author":"Buxton EC","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00126839-200304040-00003","article-title":"ALX 111: ALX1-11, parathyroid hormone (1-84) - NPS Allelix, PREOS, PTH, recombinant human parathyroid hormone, rhPTH (1-84)","volume":"4","year":"2003","journal-title":"Drugs R D."},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00198-002-1312-0","article-title":"Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis","volume":"14","author":"Rehman Q","year":"2003","journal-title":"Osteoporos Int."},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1359\/jbmr.2000.15.5.944","article-title":"Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial","volume":"15","author":"Lane NE","year":"2000","journal-title":"J Bone Miner Res."},{"issue":"8","key":"ref21","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI3914","article-title":"Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: Results of a randomized controlled clinical trial","volume":"102","author":"Lane NE","year":"1998","journal-title":"J Clin Invest."},{"issue":"3","key":"ref22","first-page":"788","article-title":"Parathyroid responsivity in postmenopausal women with osteoporosis during treatment with parathyroid hormone","volume":"83","author":"Cosman F","year":"1998","journal-title":"vJ Clin Endocrinol Metab."},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0169-6009(90)90080-Y","article-title":"Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients","volume":"9","author":"Hodsman AB","year":"1990","journal-title":"Bone Miner."},{"issue":"9","key":"ref24","first-page":"3069","article-title":"Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers","volume":"85","author":"Kurland ES","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00198-004-1713-3","article-title":"Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy","volume":"16","author":"Kaufman JM","year":"2005","journal-title":"Osteoporos Int."},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide: human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll ES","year":"2003","journal-title":"J Bone Miner Res."},{"issue":"11","key":"ref27","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","article-title":"Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure","volume":"18","author":"Jiang Y","year":"2003","journal-title":"J Bone Miner Res."},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S8756-3282(00)00316-1","article-title":"Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis","volume":"27","author":"Hodsman AB","year":"2000","journal-title":"Bone."},{"issue":"11","key":"ref29","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1210\/jc.2003-030768","article-title":"Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis","volume":"88","author":"Hodsman AB","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"issue":"13","key":"ref30","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black DM","year":"2003","journal-title":"N Engl J Med."},{"issue":"2","key":"ref31","first-page":"620","article-title":"A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis","volume":"82","author":"Hodsman AB","year":"1997","journal-title":"J Clin Endocrinol Metab."},{"issue":"19","key":"ref32","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer RM","year":"2001","journal-title":"N Engl J Med."},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1359\/jbmr.2003.18.1.18","article-title":"The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis","volume":"18","author":"Marcus R","year":"2003","journal-title":"J Bone Miner Res."},{"issue":"10","key":"ref34","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis","volume":"87","author":"Body JJ","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"issue":"9077","key":"ref35","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on estrogen with osteoporosis","volume":"350","author":"Lindsay R","year":"1997","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"issue":"24","key":"ref36","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM199412153312404","article-title":"Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency","volume":"331","author":"Finkelstein JS","year":"1994","journal-title":"N Engl J Med."}],"container-title":["Sao Paulo Medical Journal"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/spmj\/v126n5\/07.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T12:30:57Z","timestamp":1558009857000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1516-31802008000500007&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S1516-31802008000500007"],"URL":"https:\/\/doi.org\/10.1590\/s1516-31802008000500007","relation":{},"ISSN":["1516-3180"],"issn-type":[{"value":"1516-3180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}